Ascentage Pharma Group International
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ASPHF research report →
Companywww.ascentagepharma.com
Ascentage Pharma Group International, a clinical-stage biotechnology company, engages in developing therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in the United States and Mainland China. Its primary product HQP1351, a BCR-ABL inhibitor targeting BCR-ABL mutants, including those with the T315I mutation, as well as for patients with tyrosine kinase inhibitor resistant chronic phase chronic myeloid leukemia. It also has APG-2575, an orally administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors, which is under Phase Ib/II clinical study; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interaction for treating solid tumors and hematological malignancies; and APG-1387, a small molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection.
- CEO
- Dajun Yang
- IPO
- 2021
- Employees
- 567
- HQ
- Suzhou, CN
Price Chart
Valuation
- Market Cap
- $3.17B
- P/E
- -10.12
- P/S
- 22.02
- P/B
- 9.41
- EV/EBITDA
- -10.78
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 84.09%
- Op Margin
- -210.40%
- Net Margin
- -216.71%
- ROE
- -123.74%
- ROIC
- -33.75%
Growth & Income
- Revenue
- $559.30M · -42.97%
- Net Income
- $-1,210,698,288 · -198.62%
- EPS
- $-3.43 · -150.36%
- Op Income
- $-1,180,905,484
- FCF YoY
- -785.91%
Performance & Tape
- 52W High
- $10.65
- 52W Low
- $5.05
- 50D MA
- $8.48
- 200D MA
- $8.85
- Beta
- 0.72
- Avg Volume
- 167.169
Get TickerSpark's AI analysis on ASPHF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our ASPHF Coverage
We haven't published any research on ASPHF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ASPHF Report →